Ride-hailing giant Uber is buying the electric bike startup JUMP Bikes, adding bikeshare to its transportation options.

In a blog post Monday morning, Uber Chief Executive Dara Khosrowshahi said the company had reached a deal to acquire JUMP, which operates dockless bikesharing services in the District of Columbia and San Francisco.

The terms of the agreement were not disclosed, but TechCrunch reported last week that the sale could exceed $100 million.

“We’re committed to bringing together multiple modes of transportation within the Uber app-so that you can choose the fastest or most affordable way to get where you’re going, whether that’s in an Uber, on a bike, on the subway, or more,” Khosrowshahi said.

The deal comes a few months after Uber launched a pilot program to integrate JUMP services into the Uber app in San Francisco. The pilot, which allows Uber riders to find and reserve the bikes through the Uber app, is “off to a very strong start,” Khosrowshahi said.

Both Uber and JUMP say the goal is offer multiple modes of transportation within the Uber app.

The bikes feature an electric motor in the front wheel. It costs $2 for 30 minutes of ride time.

A coalition of child advocates and consumer groups is asking the Federal Trade Commission to investigate YouTube for allegedly violating children’s online privacy by collecting kids’ data and targeting ads to them.

A complaint scheduled to be filed Monday with the FTC argues that Google, which owns YouTube, has profited off the collection of personal data from children who watch cartoons and other videos on the platform.

YouTube says it will review the complaint and consider ways to improve.

Its terms of service say it’s not for children under 13, but the platform is widely popular among children of all ages.

An FTC spokeswoman says the agency hasn’t yet received the complaint.

U.S. health officials are placing new restrictions on a permanent contraceptive implant that has been subject to reports of painful complications from thousands of women. But the metal implant called Essure will remain on the market.

The Food and Drug Administration said Monday that only women who read and sign a brochure about the risks of the device will be able to receive the implant made by Bayer.

Patients have reported cases of pain, bleeding and allergic reactions and cases where the implant punctured the uterus or shifted out of place.

The FDA ordered Bayer to conduct a follow-up study of the device’s safety in 2016.